Evidence map›Paper›PMID 30241141›Full record

ArticleJournal of global oncology2018

Breast Cancer Pathology Turnaround Time in Botswana.

Yehoda M Martei, Mohan Narasimhamurthy, Pooja Prabhakar, Jeré Hutson, Dipho I Setlhako, Sebathu Chiyapo, Doreen Ramogola-Masire, Ignetious Makozhombwe, Michael Feldman, Mukendi K A Kayembe and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of global oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yehoda M MarteiYehoda M. Martei, Jeré Hutson, Doreen Ramogola-Masire, Michael Feldman, and Surbhi Grover, University of Pennsylvania, Philadelphia, PA; Mohan Narasimhamurthy, Doreen Ramogola-Masire, and Mukendi K.A. Kayembe, University of Botswana; Dipho I. Setlhako and Surbhi Grover, Princess Marina Hospital; Sebathu Chiyapo, Gaborone Private Hospital; Doreen Ramogola-Masire and Surbhi Grover, Botswana University of Pennsylvania Partnership; Ignetious Makozhombwe, Diagnofirm Medical Laboratories; Mukendi K.A. Kayembe, National Health Laboratory, Gaborone, Botswana; and Pooja Prabhakar, University of Texas Southwestern Medical Center, Dallas, TX.
Mohan NarasimhamurthyYehoda M. Martei, Jeré Hutson, Doreen Ramogola-Masire, Michael Feldman, and Surbhi Grover, University of Pennsylvania, Philadelphia, PA; Mohan Narasimhamurthy, Doreen Ramogola-Masire, and Mukendi K.A. Kayembe, University of Botswana; Dipho I. Setlhako and Surbhi Grover, Princess Marina Hospital; Sebathu Chiyapo, Gaborone Private Hospital; Doreen Ramogola-Masire and Surbhi Grover, Botswana University of Pennsylvania Partnership; Ignetious Makozhombwe, Diagnofirm Medical Laboratories; Mukendi K.A. Kayembe, National Health Laboratory, Gaborone, Botswana; and Pooja Prabhakar, University of Texas Southwestern Medical Center, Dallas, TX.
Pooja PrabhakarYehoda M. Martei, Jeré Hutson, Doreen Ramogola-Masire, Michael Feldman, and Surbhi Grover, University of Pennsylvania, Philadelphia, PA; Mohan Narasimhamurthy, Doreen Ramogola-Masire, and Mukendi K.A. Kayembe, University of Botswana; Dipho I. Setlhako and Surbhi Grover, Princess Marina Hospital; Sebathu Chiyapo, Gaborone Private Hospital; Doreen Ramogola-Masire and Surbhi Grover, Botswana University of Pennsylvania Partnership; Ignetious Makozhombwe, Diagnofirm Medical Laboratories; Mukendi K.A. Kayembe, National Health Laboratory, Gaborone, Botswana; and Pooja Prabhakar, University of Texas Southwestern Medical Center, Dallas, TX.
Jeré HutsonYehoda M. Martei, Jeré Hutson, Doreen Ramogola-Masire, Michael Feldman, and Surbhi Grover, University of Pennsylvania, Philadelphia, PA; Mohan Narasimhamurthy, Doreen Ramogola-Masire, and Mukendi K.A. Kayembe, University of Botswana; Dipho I. Setlhako and Surbhi Grover, Princess Marina Hospital; Sebathu Chiyapo, Gaborone Private Hospital; Doreen Ramogola-Masire and Surbhi Grover, Botswana University of Pennsylvania Partnership; Ignetious Makozhombwe, Diagnofirm Medical Laboratories; Mukendi K.A. Kayembe, National Health Laboratory, Gaborone, Botswana; and Pooja Prabhakar, University of Texas Southwestern Medical Center, Dallas, TX.
Dipho I SetlhakoYehoda M. Martei, Jeré Hutson, Doreen Ramogola-Masire, Michael Feldman, and Surbhi Grover, University of Pennsylvania, Philadelphia, PA; Mohan Narasimhamurthy, Doreen Ramogola-Masire, and Mukendi K.A. Kayembe, University of Botswana; Dipho I. Setlhako and Surbhi Grover, Princess Marina Hospital; Sebathu Chiyapo, Gaborone Private Hospital; Doreen Ramogola-Masire and Surbhi Grover, Botswana University of Pennsylvania Partnership; Ignetious Makozhombwe, Diagnofirm Medical Laboratories; Mukendi K.A. Kayembe, National Health Laboratory, Gaborone, Botswana; and Pooja Prabhakar, University of Texas Southwestern Medical Center, Dallas, TX.
Sebathu ChiyapoYehoda M. Martei, Jeré Hutson, Doreen Ramogola-Masire, Michael Feldman, and Surbhi Grover, University of Pennsylvania, Philadelphia, PA; Mohan Narasimhamurthy, Doreen Ramogola-Masire, and Mukendi K.A. Kayembe, University of Botswana; Dipho I. Setlhako and Surbhi Grover, Princess Marina Hospital; Sebathu Chiyapo, Gaborone Private Hospital; Doreen Ramogola-Masire and Surbhi Grover, Botswana University of Pennsylvania Partnership; Ignetious Makozhombwe, Diagnofirm Medical Laboratories; Mukendi K.A. Kayembe, National Health Laboratory, Gaborone, Botswana; and Pooja Prabhakar, University of Texas Southwestern Medical Center, Dallas, TX.
Doreen Ramogola-MasireYehoda M. Martei, Jeré Hutson, Doreen Ramogola-Masire, Michael Feldman, and Surbhi Grover, University of Pennsylvania, Philadelphia, PA; Mohan Narasimhamurthy, Doreen Ramogola-Masire, and Mukendi K.A. Kayembe, University of Botswana; Dipho I. Setlhako and Surbhi Grover, Princess Marina Hospital; Sebathu Chiyapo, Gaborone Private Hospital; Doreen Ramogola-Masire and Surbhi Grover, Botswana University of Pennsylvania Partnership; Ignetious Makozhombwe, Diagnofirm Medical Laboratories; Mukendi K.A. Kayembe, National Health Laboratory, Gaborone, Botswana; and Pooja Prabhakar, University of Texas Southwestern Medical Center, Dallas, TX.
Ignetious MakozhombweYehoda M. Martei, Jeré Hutson, Doreen Ramogola-Masire, Michael Feldman, and Surbhi Grover, University of Pennsylvania, Philadelphia, PA; Mohan Narasimhamurthy, Doreen Ramogola-Masire, and Mukendi K.A. Kayembe, University of Botswana; Dipho I. Setlhako and Surbhi Grover, Princess Marina Hospital; Sebathu Chiyapo, Gaborone Private Hospital; Doreen Ramogola-Masire and Surbhi Grover, Botswana University of Pennsylvania Partnership; Ignetious Makozhombwe, Diagnofirm Medical Laboratories; Mukendi K.A. Kayembe, National Health Laboratory, Gaborone, Botswana; and Pooja Prabhakar, University of Texas Southwestern Medical Center, Dallas, TX.
Michael FeldmanYehoda M. Martei, Jeré Hutson, Doreen Ramogola-Masire, Michael Feldman, and Surbhi Grover, University of Pennsylvania, Philadelphia, PA; Mohan Narasimhamurthy, Doreen Ramogola-Masire, and Mukendi K.A. Kayembe, University of Botswana; Dipho I. Setlhako and Surbhi Grover, Princess Marina Hospital; Sebathu Chiyapo, Gaborone Private Hospital; Doreen Ramogola-Masire and Surbhi Grover, Botswana University of Pennsylvania Partnership; Ignetious Makozhombwe, Diagnofirm Medical Laboratories; Mukendi K.A. Kayembe, National Health Laboratory, Gaborone, Botswana; and Pooja Prabhakar, University of Texas Southwestern Medical Center, Dallas, TX.
Mukendi K A KayembeYehoda M. Martei, Jeré Hutson, Doreen Ramogola-Masire, Michael Feldman, and Surbhi Grover, University of Pennsylvania, Philadelphia, PA; Mohan Narasimhamurthy, Doreen Ramogola-Masire, and Mukendi K.A. Kayembe, University of Botswana; Dipho I. Setlhako and Surbhi Grover, Princess Marina Hospital; Sebathu Chiyapo, Gaborone Private Hospital; Doreen Ramogola-Masire and Surbhi Grover, Botswana University of Pennsylvania Partnership; Ignetious Makozhombwe, Diagnofirm Medical Laboratories; Mukendi K.A. Kayembe, National Health Laboratory, Gaborone, Botswana; and Pooja Prabhakar, University of Texas Southwestern Medical Center, Dallas, TX.
Surbhi GroverYehoda M. Martei, Jeré Hutson, Doreen Ramogola-Masire, Michael Feldman, and Surbhi Grover, University of Pennsylvania, Philadelphia, PA; Mohan Narasimhamurthy, Doreen Ramogola-Masire, and Mukendi K.A. Kayembe, University of Botswana; Dipho I. Setlhako and Surbhi Grover, Princess Marina Hospital; Sebathu Chiyapo, Gaborone Private Hospital; Doreen Ramogola-Masire and Surbhi Grover, Botswana University of Pennsylvania Partnership; Ignetious Makozhombwe, Diagnofirm Medical Laboratories; Mukendi K.A. Kayembe, National Health Laboratory, Gaborone, Botswana; and Pooja Prabhakar, University of Texas Southwestern Medical Center, Dallas, TX.

Funding

Shared Resources CoreU54CA190158 · NCI · UNIVERSITY OF PENNSYLVANIA · PI ROBERTSON, ERLE S. · 2014 to 2023
$4.2M
NCI NIH HHS U54 CA190158
6 · The paper itself

Abstract

purposeQuality pathology is critical for timely diagnosis and management of breast cancer. Few studies have analyzed pathology turnaround time (TAT) in sub-Saharan Africa. The purpose of this study was to quantify TAT for breast cancer specimens processed by the National Health Laboratory and Diagnofirm Laboratory in Gaborone, Botswana, and additionally compare TAT before and after 2012 to evaluate the effect of pathology scale-up interventions by the Ministry of Health and Wellness.

methodsRetrospective analyses of TAT were performed for breast specimens submitted to the two laboratories from 2011 to 2015. TAT was calculated as the time from specimen collection and receipt in the laboratory to the date of final report sign-out. Descriptive statistics and rank sum test were used to compare temporal trends in TAT before and after 2012.

resultsA total of 158 breast biopsy, 219 surgical, and 218 immunohistochemistry (IHC) specimens were analyzed. The median TAT in 2015 was 6 and 7 days for biopsy and IHC specimens, respectively, and 57.5 days for surgical specimens. There was a significant decrease in median TAT for biopsy specimens from 21.5 days in 2011 to 2012 compared with 8 days in 2013 to 2015 ( P < .001). There was also a significant decrease in median TAT for IHC specimens during the same period ( P < .001). However, there was no significant decline in median TAT for surgical specimens.

conclusionThe scale-up of pathology personnel and infrastructure by the Ministry of Health and Wellness significantly reduced median TAT for biopsy and IHC specimens. TAT for surgical specimens remains suboptimal. Efforts are currently under way to decrease TAT for surgical specimens to 7 days.

Indexed as

BotswanaBreast NeoplasmsFemaleHumansRetrospective Studies

Identifiers

PMID30241141
PMCPMC6180776

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.